Pfizer Inc. (PFE)
Pfizer: One Of The Next Big AI Winners
Kirk Spano thinks Pfizer is poised to be a major AI winner, especially in cancer treatment. Potentially making it easier to manage like AIDS.
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
Pfizer (PFE 0.23%) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market. The company generated billions of dollars in revenue thanks to its coronavirus vaccine and treatment, even reaching a record of more than $100 billion in total company revenue in 2022.
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
Pfizer (PFE) closed the most recent trading day at $26.56, moving -0.67% from the previous trading session.
Better Income Stock: Pfizer or Altria Group?
High-yield dividend stocks often catch investors' attention -- and for good reason. When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.
Should Value Investors Buy Pfizer (PFE) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's valuation at 9x 2025 EPS and a 6.5% dividend yield make it attractive for long-term investors. Management's 2025 guidance indicates flat sales but improved profitability, with gross margins expected to reach the upper 70s, enhancing shareholder value and supporting its strong dividend payouts.
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.
Why Pfizer (PFE) Dipped More Than Broader Market Today
Pfizer (PFE) concluded the recent trading session at $25.77, signifying a -0.46% move from its prior day's close.
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Shares of Pfizer (PFE -2.04%) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead.
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)
Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent institutional selling, and relative strength has deteriorated, underperforming the S&P 500 since July 2024. Pfizer stock is in a consolidation phase, potentially setting up for a bull run if it can recapture its 30-week EMA and show bullish volume.
